Companies are adjusting their organisational structure, capacities, and resourcing because JCA centralizes the clinical domains of the HTA process
Updates
Insights on Centers for Medicare and Medicaid Services (CMS) Updates for IPAY 2027
Submission is subject to the EU HTA Regulation, which applies to all new oncology drugs and cell and gene therapies beginning January 2025, orphan medicinal products starting January 2028, and lastly, all new drugs from 2030 onward
Contributed by: Ari Gnanasakthy, MBA, MScPrincipal Scientist, Patient-Centered Outcomes AssessmentRTI Health Solutions
Now is the time for drug manufacturers to do everything they can to get ready for a potential submission in support of their product for Medicare's Drug Price Negotiation (DPN) program.
Drug and medical device developers are looking to understand the potential implications of joint clinical assessments and Medicare price negotiations
ASCO 2024 demonstrated the incredible efforts of the oncology community to push the boundaries of cancer treatment
Big changes in US Medicare drug pricing and EU Health Technology Assessment regulations. Enter Joint Clinical Assessments.
Jennifer Alkire, PharmD, Senior Associate, Value & Access, attended AMCP 2024 and brings back these insights.
The 2024 America’s Best Employers for Diversity rankings resulted from surveying 170,000 US employees
Strategic collaboration follows RTI’s equity investment in advanced tech-enabled research services
When causal inference is applied to pharmacoepidemiology, researchers can estimate which treatments are helpful or harmful.
Institute commits additional $9 million to internal sustainability investments to reduce GHG emissions
Viewers can explore community-level risk of inequities in life expectancy, cancer mortality, drug overdoses and more
Simmons will drive ambitious strategic growth to expand our ability to serve our clients’ needs, enhance our solution offerings, and increase our impact on patient well-being.
Gather information on long-term treatment effects by integrating data from existing studies into a pooled database for analysis.
The rankings acknowledge RTI as a family-friendly workplace in addition to a previous award as one of America’s Greatest Workplaces overall this year
For the 6th year in a row, RTI International (RTI Health Solutions' parent company) has earned the 2023 Military Friendly® Employer designation.
Biomedical, pharmaceutical, and healthcare entities are recognizing their crucial role in addressing health disparities.
Regulatory considerations for both preapproval and postapproval studies. Highlighting early engagement with the FDA at the study design stage.
Research must recognize and explore the multiple drivers of people’s healthcare experiences and outcomes to address inequity.
Article contributed by Naoko Ronquest (she/her), PhD, Executive Director, US HTA Strategy and Early Modeling
The award recognizes RTI’s commitment to providing a positive work environment and creating a culture of belonging